索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]毕文丽,艾比班木?,艾则孜,等.血清载脂蛋白C3与心血管疾病[J].国际心血管病杂志,2022,05:275-277.
点击复制

血清载脂蛋白C3与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2022年05期
页码:
275-277
栏目:
综述
出版日期:
2022-10-01

文章信息/Info

Title:
-
作者:
毕文丽; 艾比班木?; 艾则孜; 马依彤
830054 乌鲁木齐，新疆医科大学第一附属医院心脏中 心冠心病科
Author(s):
-
关键词:
载脂蛋白C3 ; 血脂代谢紊乱; 动脉粥样硬化; 心血管疾病
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2022.05.006
文献标识码:
-
摘要:
载脂蛋白C3 是天然脂蛋白酯酶抑制剂，研究显示载脂蛋白C3 在动脉粥样硬化、 心肌梗死及代谢紊乱等疾病的病理生理过程中发挥重要作用。
Abstract:
-

参考文献/References

[1] Brown WV, Levy RI, Fredrickson DS. Studies of the proteins in human plasma very low density lipoproteins[J]. J Biol Chem, 1969, 244(20):5687-5694.
[2] Borén J, Packard CJ, Taskinen MR. The roles of ApoC-Ⅲ on the metabolism of triglyceride-rich lipoproteins in humans[J]. Front Endocrinol (Lausanne), 2020, 11:474.
[3] Basu D, Goldberg IJ. Regulation of lipoprotein lipasemediated lipolysis of triglycerides[J]. Curr Opin Lipidol, 2020, 31(3):154-160.
[4] J?rgensen AB, Frikke-Schmidt R, Nordestgaard BG, et al. Loss-of-function mutations in apoc3 and risk of ischemic vascular disease[J]. N Engl J Med, 2014, 371(1):32-41.
[5] Wolf D, Ley K. Immunity and inflammation in atherosclerosis[J]. Circ Res, 2019, 124(2):315-327.
[6] Goyal S, Tanigawa Y, Zhang W, et al. Apoc3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups[J]. Lipids Health Dis, 2021, 20(1):113.
[7] Stitziel NO, Kanter JE, Bornfeldt KE. Emerging targets for cardiovascular disease prevention in diabetes[J]. Trends Mol Med, 2020, 26(8):744-757.
[8] Yan H, Niimi M, Matsuhisa F, et al. Apolipoprotein CⅢ deficiency protects against atherosclerosis in knockout rabbits[J]. Arterioscler Thromb Vasc Biol, 2020，40(9):2095- 2107.
[9] Dib I, Khalil A, Chouaib R, et al. Apolipoprotein C-Ⅲ and cardiovascular diseases: when genetics meet molecular pathologies[J]. Mol Biol Rep, 2021, 48(1):875-886.
[10] Basu D, Bornfeldt KE. Hypertriglyceridemia and atherosclerosis: using human research to guide mechanistic studies in animal models[J]. Front Endocrinol (Lausanne), 2020, 11:504.
[11] Zewinger S, Reiser J, Jankowski V, et al. Apolipoprotein c3 induces inflammation and organ damage by alternative inflammasome activation[J]. Nat Immunol, 2020, 21(1):30-41.
[12] Akoumianakis I, Zvintzou E, Kypreos K, et al. Angptl3 and apolipoprotein C-Ⅲ as novel lipid-lowering targets[J]. Curr Atheroscler Rep, 2021, 23(5):20.
[13] Lee SJ, Mahankali M, Bitar A, et al. A novel role for rarα agonists as apolipoprotein c3 inhibitors identified from high throughput screening[J]. Sci Rep, 2017, 7(1):5824.
[14] Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in, APOC3, triglycerides, and coronary disease[J]. N Engl J Med, 2014, 371:22-31.
[15] Pollin TI, Damcott CM, Shen H, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection[J]. Science, 2008, 322(5908):1702-1705.
[16] Crawford DC, Dumitrescu L, Goodloe R, et al. Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the Epidemiologic Architecture for Genes Linked to Environment Study[J]. Circ Cardiovasc Genet, 2014, 7(6):848-853.
[17] Olkkonen VM, Sinisalo J, Jauhiainen M. New medications targeting triglyceride-rich lipoproteins: can inhibition of ANGPTL3 or apoC-Ⅲ reduce the residual cardiovascular risk?[J]. Atherosclerosis, 2018, 272:27-32.
[18] Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein c-iii or angiopoietin like protein 3 reduce cardiovascular disease?[J]. Curr Opin Lipidol, 2020, 31(3):140-146.
[19] Hussain A, Ballantyne CM, Saeed A, et al. Triglycerides and ASCVD risk reduction: recent insights and future directions[J]. Curr Atheroscler Rep, 2020, 22(7):25.
[20] Muller MP, Wang Y, Morrissey JH, et al. Lipid specificity of the membrane binding domain of coagulation factor X[J]. J Thromb Haemost, 2017, 15(10):2005-2016.
[21] Martinelli N, Baroni M, Castagna A, et al. Apolipoprotein C-Ⅲ strongly correlates with activated factor vii-anti-thrombin complex: an additional link between plasma lipids and coagulation[J]. Thromb Haemost, 2019, 119(2):192-202.
[22] Olivieri O, Turcato G, Moruzzi S, et al. Not just arterial damage: increased incidence of venous thromboembolic events in cardiovascular patients with elevated plasma levels of apolipoprotein CIII[J]. J Am Heart Assoc, 2019, 8(2):e010973.
[23] Altomonte J, Cong L, Harbaran S, et al. Foxo1 mediates insulin action on apoC-Ⅲ and triglyceride metabolism[J]. J Clin Invest, 2004, 114(10):1493-1503.
[24] Nurmohamed NS, Dallinga-Thie GM, Stroes ESG. Targeting apoC-Ⅲ and ANGPTL3 in the treatment of hypertriglyceridemia[J]. Expert Rev Cardiovasc Ther, 2020, 18(6):355-361.
[25] Karásek D. Combined lipid-lowering therapy[J]. Vnitr Lek, 2019, 64(12):1177-1184.
[26] Gouni-Berthold I. The role of antisense oligonucleotide therapy against apolipoprotein-ciii in hypertrigly ceridemia[J]. Atheroscler Suppl, 2017, 30:19-27.
[27] Graham MJ, Lee RG, Bell TA, et al. Antisense oligonucleotide inhibition of apolipoprotein C-Ⅲ reduces plasma triglycerides in rodents, nonhuman primates, and humans[J]. Circ Res, 2013, 112(11):1479-1490.

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（91957208）；新疆维吾尔自治区重 点实验室开放课题（2020D04008）
通信作者：马依彤， E-mail：myt-xj@163.com
更新日期/Last Update: 2022-10-01